1H-magnetic resonance spectroscopy (1H-MRS) in methamphetamine dependence and methamphetamine induced psychosis

Schizophrenia Research

Volumn 153, Issue 1-3, 2014, Pages 122-128

  Howells, Fleur M ^a   Uhlmann, Anne ^a   Temmingh, Henk ^a   Sinclair, Heidi ^a   Meintjes, Ernesta ^a   Wilson, Don ^a   Stein, Dan J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Anterior cingulate cortex (ACC); Dorsolateral prefrontal cortex (DLPFC); Frontal white matter; Methamphetamine (MA); N Acetyl aspartate (NAA); Psychosis

Indexed keywords

CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; METHAMPHETAMINE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHOSPHORYLCHOLINE; ASPARTIC ACID; CHOLINE; N-ACETYLASPARTATE; PROTON;

ADULT; ANTERIOR CINGULATE; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GRAY MATTER; HUMAN; MALE; METHAMPHETAMINE DEPENDENCE; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROIMAGING; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SYMPTOM ASSESSMENT; WHITE MATTER; ADOLESCENT; ANALOGS AND DERIVATIVES; BRAIN; DIAGNOSTIC USE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; FEMALE; GLUTAMINE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHAMPHETAMINE; PREFRONTAL CORTEX; PROTONS; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84895788524     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.029     Document Type: Article

References (51)

1. Alexopoulos G.S., Murphy C.F., Gunning-Dixon F.M., Latoussakis V., Kanellopoulos D., Klimstra S., Lim K.O., Hoptman M.J. Microstructural white matter abnormalities and remission of geriatric depression. Am. J. Psychiatry 2008, 165(2):238-244.
2. Bell D.S. The experimental reproduction of amphetamine psychosis. Arch. Gen. Psychiatry 1973, 29(1):35-40.
3. Bertolino A., Breier A., Callicott J.H., Adler C., Mattay V.S., Shapiro M., Frank J.A., Pickar D., Weinberger D.R. The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000, 22(2):125-132.
4. Bjartmar C., Battistuta J., Terada N., Dupree E., Trapp B.D. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 2002, 51(1):51-58.
5. Buffenstein A., Heaster J., Ko P. Chronic psychotic illness from methamphetamine. Am. J. Psychiatry 1999, 156(4):662.
6. Bustillo J., Wolff C., Myers-y-Gutierrez A., Dettmer T.S., Cooper T.B., Allan A., Lauriello J., Valenzuela C.F. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr. Res. 2004, 66(1):31-39.
7. Bustillo J.R., Lauriello J., Rowland L.M., Jung R.E., Petropoulos H., Hart B.L., Blanchard J., Keith S.J., Brooks W.M. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001, 107(3):135-149.
8. Bustillo J.R., Rowland L.M., Jung R., Brooks W.M., Qualls C., Hammond R., Hart B., Lauriello J. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008, 33(10):2456-2466.
9. Caton C.L., Hasin D.S., Shrout P.E., Drake R.E., Dominguez B., First M.B., Samet S., Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br. J. Psychiatry 2007, 190:105-111.
10. Deicken R.F., Zhou L., Schuff N., Weiner M.W. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr. Res. 1997, 27(1):65-71.
11. Dennis M. Developmental plasticity in children: the role of biological risk, development, time, and reserve. J. Commun. Disord. 2000, 33(4):321-331. (quiz 332).
12. Ernst T., Chang L. Adaptation of brain glutamate plus glutamine during abstinence from chronic methamphetamine use. J. Neuroimmune Pharmacol. 2008, 3(3):165-172.
13. 1H-MRS study. Neurology 2000, 54(6):1344-1349.
14. Fiorentini A., Volonteri L.S., Dragogna F., Rovera C., Maffini M., Mauri M.C., Altamura C.A. Substance-induced psychoses: a critical review of the literature. Curr. Drug Abus. Rev. 2011, 4(4):228-240.
15. First M.B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version 1997, American Psychiatric Press, Washington, DC.
16. Goldstein G., Panchalingam K., McClure R.J., Stanley J.A., Calhoun V.D., Pearlson G.D., Pettegrew J.W. Molecular neurodevelopment: an in vivo 31P-1H MRSI study. J. Int. Neuropsychol. Soc. 2009, 15(5):671-683.
17. Gururajan A., Manning E.E., Klug M., van den Buuse M. Drugs of abuse and increased risk of psychosis development. Aust. N. Z. J. Psychiatry 2012, 46(12):1120-1135.
18. Harte M.K., Bachus S.B., Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 2005, 75(2-3):303-308.
19. He J., Kong J., Tan Q.R., Li X.M. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adhes. Migr. 2009, 3(1):129-137.
20. Huang Y.N., Wu C.H., Lin T.C., Wang J.Y. Methamphetamine induces heme oxygenase-1 expression in cortical neurons and glia to prevent its toxicity. Toxicol. Appl. Pharmacol. 2009, 240(3):315-326.
21. Iwanami A., Sugiyama A., Kuroki N., Toda S., Kato N., Nakatani Y., Horita N., Kaneko T. Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatr. Scand. 1994, 89(6):428-432.
22. Jonsson L.E., Sjostrom K. A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis. Br. J. Psychiatry 1970, 117(541):661-665.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Lindquist D.M., Dunn R.S., Cecil K.M. Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study. Schizophr. Res. 2011, 128(1-3):83-90.
25. Marshall B.D., Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010, 105(6):991-1002.
26. Mathias S., Lubman D.I., Hides L. Substance-induced psychosis: a diagnostic conundrum. J. Clin. Psychiatry 2008, 69(3):358-367.
27. Molina V., Martin C., Ballesteros A., de Herrera A.G., Hernandez-Tamames J.A. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261(6):407-416.
28. Molina V., Sanchez J., Reig S., Sanz J., Benito C., Santamarta C., Pascau J., Sarramea F., Gispert J.D., Misiego J.M., Palomo T., Desco M. N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophr. Res. 2005, 73(2-3):209-219.
29. Molina V., Sanchez J., Sanz J., Reig S., Benito C., Leal I., Sarramea F., Rebolledo R., Palomo T., Desco M. Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. Eur. Psychiatry 2007, 22(8):505-512.
30. Moore G.J., Galloway M.P. Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol. Bull. 2002, 36(2):5-23.
31. Nordahl T.E., Salo R., Natsuaki Y., Galloway G.P., Waters C., Moore C.D., Kile S., Buonocore M.H. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry 2005, 62(4):444-452.
32. Nordahl T.E., Salo R., Possin K., Gibson D.R., Flynn N., Leamon M., Galloway G.P., Pfefferbaum A., Spielman D.M., Adalsteinsson E., Sullivan E.V. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magn. Reson. Spectrosc. Psychiatry Res. 2002, 116(1-2):43-52.
33. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
34. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch. Gen. Psychiatry 1999, 56(2):185-192.
35. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 1999, 41(2):276-284.
36. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993, 30(6):672-679.
37. Rusyniak D.E. Neurologic manifestations of chronic methamphetamine abuse. Neurol. Clin. 2011, 29(3):641-655.
38. Sailasuta N., Abulseoud O., Harris K.C., Ross B.D. Glial dysfunction in abstinent methamphetamine abusers. J. Cereb. Blood Flow Metab. 2010, 30(5):950-960.
39. Sailasuta N., Abulseoud O., Hernandez M., Haghani P., Ross B.D. Metabolic abnormalities in abstinent methamphetamine dependent subjects. Subst. Abus. 2010, 2010(4):9-20.
40. Salo R., Buonocore M.H., Leamon M., Natsuaki Y., Waters C., Moore C.D., Galloway G.P., Nordahl T.E. Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study. Drug Alcohol Depend. 2011, 113(2-3):133-138.
41. Sato M. A lasting vulnerability to psychosis in patients with previous methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1992, 654:160-170.
42. Sekine Y., Minabe Y., Kawai M., Suzuki K., Iyo M., Isoda H., Sakahara H., Ashby C.R., Takei N., Mori N. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology 2002, 27(3):453-461.
43. StatSoft Incorporated STATISTICA data analysis software system 2011, 10.
44. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 2006, 59(10):929-939.
45. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10(10):900-919.
46. Sung Y.H., Cho S.C., Hwang J., Kim S.J., Kim H., Bae S., Kim N., Chang K.H., Daniels M., Renshaw P.F., Lyoo I.K. Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007, 88(1):28-35.
47. 1H MRS) study. Med. Sci. Monit. 2007, 13(Suppl. 1):17-22.
48. Truckenmiller M.E., Namboodiri M.A., Brownstein M.J., Neale J.H. N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J. Neurochem. 1985, 45(5):1658-1662.
49. Ujike H., Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann. N. Y. Acad. Sci. 2004, 1025:279-287.
50. van der Kouwe A.J., Benner T., Salat D.H., Fischl B. Brain morphometry with multiecho MPRAGE. Neuroimage 2008, 40(2):559-569.
51. WMA General Assembly World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 2000.